Sonesitatug Vedotin

DB18619InvestigationalProtein Based Therapies

CMG901 is an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload.

Mechanism
Curator reviewed
Also known as
an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload
Code names
AZD0901 · CMG-901

Resolves to

Compound
UNII96ZG83EF42
Targets
P56856CLDN18

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
8Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Sonesitatug Vedotin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In